{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:23Z","timestamp":1786369043973,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Health Science and Technology Project","award":["No. TJWJ2021ZD010"],"award-info":[{"award-number":["No. TJWJ2021ZD010"]}]},{"name":"Tianjin Health Science and Technology Project","award":["No. TJWJ2021ZD010"],"award-info":[{"award-number":["No. TJWJ2021ZD010"]}]},{"name":"Tianjin Health Science and Technology Project","award":["No. TJWJ2021ZD010"],"award-info":[{"award-number":["No. TJWJ2021ZD010"]}]},{"name":"Tianjin Health Science and Technology Project","award":["No. TJWJ2021ZD010"],"award-info":[{"award-number":["No. TJWJ2021ZD010"]}]},{"name":"Tianjin Health Science and Technology Project","award":["No. TJWJ2021ZD010"],"award-info":[{"award-number":["No. TJWJ2021ZD010"]}]},{"name":"Tianjin Health Science and Technology Project","award":["No. TJWJ2021ZD010"],"award-info":[{"award-number":["No. TJWJ2021ZD010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46177-7","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:04:05Z","timestamp":1780074245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Remnant cholesterol is independently associated with liver fibrosis in metabolic dysfunction-associated fatty liver disease patients and rats"],"prefix":"10.1038","volume":"16","author":[{"given":"Ruifang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"46177_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mam.2016.11.008","volume":"54","author":"J Lee","year":"2017","unstructured":"Lee, J., Kim, Y., Friso, S. & Choi, S. W. Epigenetics in non-alcoholic fatty liver disease. Mol. Aspects Med. 54, 78\u201388 (2017).","journal-title":"Mol. Aspects Med."},{"issue":"8","key":"46177_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/jgh.16196","volume":"38","author":"R Li","year":"2023","unstructured":"Li, R. et al. Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index. J. Gastroenterol. Hepatol. 38 (8), 1316\u20131324 (2023).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"46177_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam, M. et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol. Int. 19 (2), 261\u2013301 (2025).","journal-title":"Hepatol. Int."},{"issue":"1","key":"46177_CR4","doi-asserted-by":"publisher","first-page":"102068","DOI":"10.1016\/j.clinre.2022.102068","volume":"47","author":"H Tian","year":"2023","unstructured":"Tian, H. et al. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019. Clin. Res. Hepatol. Gastroenterol. 47 (1), 102068 (2023).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"2","key":"46177_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jceh.2020.07.008","volume":"11","author":"A Duseja","year":"2021","unstructured":"Duseja, A., Dhiman, R. K. & Premkumar, M. Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years. J. Clin. Exp. Hepatol. 11 (2), 159\u2013162 (2021).","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"3","key":"46177_CR6","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.3390\/ijms16035161","volume":"16","author":"C Sun","year":"2015","unstructured":"Sun, C., Fan, J. G. & Qiao, L. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int. J. Mol. Sci. 16 (3), 5161\u20135179 (2015).","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"46177_CR7","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.jhep.2020.06.042","volume":"73","author":"KI Zheng","year":"2020","unstructured":"Zheng, K. I. et al. Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis. J. Hepatol. 73 (6), 1571\u20131573 (2020).","journal-title":"J. Hepatol."},{"issue":"2","key":"46177_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.22363","volume":"48","author":"K Wouters","year":"2008","unstructured":"Wouters, K. et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48 (2), 474\u2013486 (2008).","journal-title":"Hepatology"},{"issue":"5","key":"46177_CR9","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.18632\/oncotarget.6799","volume":"7","author":"DQ Sun","year":"2016","unstructured":"Sun, D. Q. et al. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget 7 (5), 5728\u20135737 (2016).","journal-title":"Oncotarget"},{"issue":"8","key":"46177_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/j.1572-0241.2004.30159.x","volume":"99","author":"N Chalasani","year":"2004","unstructured":"Chalasani, N., Deeg, M. A. & Crabb, D. W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99 (8), 1497\u20131502 (2004).","journal-title":"Am. J. Gastroenterol."},{"issue":"7","key":"46177_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/oby.2011.21","volume":"19","author":"AL Norris","year":"2011","unstructured":"Norris, A. L. et al. Circulating oxidized LDL and inflammation in extreme pediatric obesity. Obes. (Silver Spring). 19 (7), 1415\u20131419 (2011).","journal-title":"Obes. (Silver Spring)"},{"key":"46177_CR12","doi-asserted-by":"publisher","first-page":"913977","DOI":"10.3389\/fcvm.2022.913977","volume":"9","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. The Association Between Remnant Cholesterol and the Estimated 10-Year Risk of a First Hard Cardiovascular Event. Front. Cardiovasc. Med. 9, 913977 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"46177_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.02.026","volume":"299","author":"K Konishi","year":"2020","unstructured":"Konishi, K. et al. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. Atherosclerosis 299, 32\u201337 (2020).","journal-title":"Atherosclerosis"},{"issue":"2","key":"46177_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","volume":"40","author":"PB Sandesara","year":"2019","unstructured":"Sandesara, P. B., Virani, S. S., Fazio, S. & Shapiro, M. D. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr. Rev. 40 (2), 537\u2013557 (2019).","journal-title":"Endocr. Rev."},{"issue":"4","key":"46177_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo, A. et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 61 (4), 427\u2013436 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"42","key":"46177_CR16","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","volume":"42","author":"R Quispe","year":"2021","unstructured":"Quispe, R. et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur. Heart J. 42 (42), 4324\u20134332 (2021).","journal-title":"Eur. Heart J."},{"issue":"23","key":"46177_CR17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.jacc.2020.10.029","volume":"76","author":"JR Burnett","year":"2020","unstructured":"Burnett, J. R., Hooper, A. J. & Hegele, R. A. Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk. J. Am. Coll. Cardiol. 76 (23), 2736\u20132739 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"46177_CR18","doi-asserted-by":"publisher","first-page":"1098078","DOI":"10.3389\/fendo.2023.1098078","volume":"14","author":"Y Cheng","year":"2023","unstructured":"Cheng, Y. et al. Remnant cholesterol, stronger than triglycerides, is associated with incident non-alcoholic fatty liver disease. Front. Endocrinol. (Lausanne). 14, 1098078 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"46177_CR19","unstructured":"Wang, Y. et al. Serum remnant cholesterol is a potential predictor of liver stiffness in patients with nonalcoholic fatty liver disease. Scand J. Gastroenterol 1\u201311. (2023)."},{"issue":"5","key":"46177_CR20","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/HEP.0000000000000319","volume":"78","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-\u03b2\/SMAD signaling. Hepatology 78 (5), 1433\u20131447 (2023).","journal-title":"Hepatology"},{"issue":"2","key":"46177_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (2), 289\u2013293 (1996).","journal-title":"Hepatology"},{"issue":"16","key":"46177_CR22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T. & Catapano, A. L. High-density lipoprotein revisited: biological functions and clinical relevance. Eur. Heart J. 44 (16), 1394\u20131407 (2023).","journal-title":"Eur. Heart J."},{"issue":"4","key":"46177_CR23","doi-asserted-by":"publisher","first-page":"e1598","DOI":"10.1210\/clinem\/dgab825","volume":"107","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Remnant Lipoprotein Cholesterol as a Factor Related to Adult Fatty Liver Disease. J. Clin. Endocrinol. Metab. 107 (4), e1598\u2013e1609 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"46177_CR24","doi-asserted-by":"publisher","first-page":"e3295","DOI":"10.1210\/clinem\/dgac283","volume":"107","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction-associated Fatty Liver Disease. J. Clin. Endocrinol. Metab. 107 (8), e3295\u2013e3303 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"46177_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12944-021-01573-y","volume":"20","author":"Y Zou","year":"2021","unstructured":"Zou, Y. et al. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis. 20 (1), 139 (2021).","journal-title":"Lipids Health Dis."},{"issue":"6","key":"46177_CR26","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.jhepr.2020.100150","volume":"2","author":"J Chin","year":"2020","unstructured":"Chin, J. et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. JHEP Rep. 2 (6), 100150 (2020).","journal-title":"JHEP Rep."},{"issue":"1","key":"46177_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13098-023-01220-9","volume":"15","author":"H Huang","year":"2023","unstructured":"Huang, H. et al. Remnant cholesterol and severity of nonalcoholic fatty liver disease. Diabetol. Metab. Syndr. 15 (1), 238 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"46177_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.atherosclerosis.2014.07.008","volume":"236","author":"SB Prenner","year":"2014","unstructured":"Prenner, S. B. et al. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis 236 (2), 244\u2013250 (2014).","journal-title":"Atherosclerosis"},{"key":"46177_CR29","doi-asserted-by":"crossref","unstructured":"Brunzell, J. D. et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (15), 1512-24. (2008).","DOI":"10.1016\/j.jacc.2008.02.034"},{"issue":"11","key":"46177_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman, M. J. et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32 (11), 1345\u20131361 (2011).","journal-title":"Eur. Heart J."},{"key":"46177_CR31","doi-asserted-by":"crossref","unstructured":"Joshi, P. H. et al. P. P., Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. J Am. Heart Assoc 5 (5). (2016).","DOI":"10.1161\/JAHA.115.002765"},{"issue":"4","key":"46177_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dbi19-0007","volume":"69","author":"A Chait","year":"2020","unstructured":"Chait, A. et al. Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease. Diabetes 69 (4), 508\u2013516 (2020).","journal-title":"Diabetes"},{"issue":"12","key":"46177_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo, A., Benn, M., Tybj\u00e6rg-Hansen, A. & Nordestgaard, B. G. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128 (12), 1298\u20131309 (2013).","journal-title":"Circulation"},{"key":"46177_CR34","doi-asserted-by":"crossref","unstructured":"Crosby, J. et al. A. P.; Boerwinkle, E.; S., Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 (1), 22\u201331. (2014).","DOI":"10.1056\/NEJMoa1307095"},{"issue":"7","key":"46177_CR35","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1161\/01.RES.86.7.768","volume":"86","author":"JC Rutledge","year":"2000","unstructured":"Rutledge, J. C., Mullick, A. E., Gardner, G. & Goldberg, I. J. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ. Res. 86 (7), 768\u2013773 (2000).","journal-title":"Circ. Res."},{"issue":"4","key":"46177_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","volume":"28","author":"A Varbo","year":"2017","unstructured":"Varbo, A. & Nordestgaard, B. G. Remnant lipoproteins. Curr. Opin. Lipidol. 28 (4), 300\u2013307 (2017).","journal-title":"Curr. Opin. Lipidol."},{"key":"46177_CR37","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","volume":"50","author":"J Heeren","year":"2021","unstructured":"Heeren, J. & Scheja, L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol. Metab. 50, 101238 (2021).","journal-title":"Mol. Metab."},{"issue":"5","key":"46177_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11883-022-01006-w","volume":"24","author":"X Peng","year":"2022","unstructured":"Peng, X. & Wu, H. Inflammatory Links Between Hypertriglyceridemia and Atherogenesis. Curr. Atheroscler Rep. 24 (5), 297\u2013306 (2022).","journal-title":"Curr. Atheroscler Rep."},{"issue":"8","key":"46177_CR39","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","volume":"150","author":"MV Machado","year":"2016","unstructured":"Machado, M. V. & Diehl, A. M. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology 150 (8), 1769\u20131777 (2016).","journal-title":"Gastroenterology"},{"issue":"1","key":"46177_CR40","doi-asserted-by":"publisher","first-page":"159058","DOI":"10.1016\/j.bbalip.2021.159058","volume":"1867","author":"M Darabi","year":"2022","unstructured":"Darabi, M. & Kontush, A. High-density lipoproteins (HDL): Novel function and therapeutic applications. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids. 1867 (1), 159058 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"},{"issue":"1","key":"46177_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-022-01475-y","volume":"21","author":"T Szili-Torok","year":"2022","unstructured":"Szili-Torok, T. et al. Remnant lipoprotein cholesterol is associated with incident new onset diabetes after transplantation (NODAT) in renal transplant recipients: results of the TransplantLines Biobank and cohort Studies. Cardiovasc. Diabetol. 21 (1), 41 (2022).","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46177-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:05:59Z","timestamp":1786367159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46177"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46177-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol was approved by the Ethics Committee of Tianjin Second People\u2019s Hospital and was conducted in accordance with the principles of the Declaration of Helsinki. We obtained written informed consent from all the patients, and the IRB approval number is No. [2021]55. The animal experiments were approved by the Animal Experimentation Ethics Committee of Nankai University, and the animal study approval number is 2021-SYDWLL-000338.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24660"}}